We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WST icon
126
West Pharmaceutical
WST
$24.7B
$293K 0.06%
890
-610
-41% -$216K
EDR
127
DELISTED
Endeavor Group Holdings, Inc.
EDR
$287K 0.05%
10,615
-144,635
-93% -$3.85M
TRML
128
DELISTED
Tourmaline Bio
TRML
$271K 0.05%
21,060
+9,500
+82% +$153K
MIST icon
129
Milestone Pharmaceuticals
MIST
$143M
$267K 0.05%
202,460
– –
MKSI icon
130
MKS Inc
MKSI
$21.1B
$261K 0.05%
+2,000
New +$252K
IROHU
131
DELISTED
Iron Horse Acquisitions Corp Unit
IROHU
$257K 0.05%
25,000
– –
KRRO icon
132
Korro Bio
KRRO
$166M
$244K 0.05%
+7,210
New +$398K
ELEV
133
DELISTED
Elevation Oncology
ELEV
$229K 0.04%
84,927
+76,298
+884% +$287K
CCOI icon
134
Cogent Communications
CCOI
$644M
$226K 0.04%
4,000
– –
ZROZ icon
135
PIMCO 25+ Year Zero Coupon US Treasury Index Exchange-Traded Fund
ZROZ
$1.28B
$225K 0.04%
3,000
– –
OCUL icon
136
Ocular Therapeutix
OCUL
$1.87B
$225K 0.04%
+32,900
New +$203K
SLRN
137
DELISTED
ACELYRIN
SLRN
$223K 0.04%
50,521
+35,500
+236% +$166K
OLMA icon
138
Olema Pharmaceuticals
OLMA
$1.01B
$217K 0.04%
+20,076
New +$218K
VERV
139
DELISTED
Verve Therapeutics
VERV
$215K 0.04%
+44,000
New +$277K
MLTX icon
140
MoonLake Immunotherapeutics
MLTX
$1.49B
$211K 0.04%
4,800
+1,800
+60% +$76.2K
INBS icon
141
Intelligent Bio Solutions
INBS
$4.28M
$208K 0.04%
10,825
– –
AMLX icon
142
Amylyx Pharmaceuticals
AMLX
$2.43B
$204K 0.04%
107,306
+68,448
+176% +$133K
MREO
143
Mereo BioPharma
MREO
$48.4M
$199K 0.04%
+55,400
New +$179K
SPRB
144
Spruce Biosciences
SPRB
$128M
$184K 0.03%
4,736
-134
-3% -$7.18K
TLT icon
145
iShares 20+ Year Treasury Bond ETF
TLT
$41.8B
$184K 0.03%
2,000
– –
XENE icon
146
Xenon Pharmaceuticals
XENE
$6.22B
$183K 0.03%
+4,700
New +$188K
BCRX icon
147
BioCryst Pharmaceuticals
BCRX
$2.31B
$182K 0.03%
+29,400
New +$162K
IOVA icon
148
Iovance Biotherapeutics
IOVA
$1.94B
$180K 0.03%
22,400
+17,400
+348% +$186K
GLRE icon
149
Greenlight Captial
GLRE
$522M
$162K 0.03%
12,385
-1,000
-7% -$12.7K
NVEI
150
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
$162K 0.03%
5,000
– –
4 5
6
7 8

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.